Zacks Investment Research on MSN
Agio's Pyrukynd gets approval for thalassemia in Europe
Agios Pharmaceuticals AGIO announced that its lead drug, Pyrukynd (mitapivat), an oral pyruvate kinase (PK) activator, has ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Investors in Agios Pharmaceuticals Inc (Symbol: AGIO) saw new options become available this week, for the May 2026 expiration. One of the key inputs that goes into the price an option buyer is willing ...
Why Agios Pharmaceuticals (AGIO) is on investors’ radar today Agios Pharmaceuticals (AGIO) has drawn investor attention after recent share price moves, with the stock last closing at US$28.73 and ...
Agio, a leading hybrid cybersecurity and managed IT organization, is debuting a new AI-enabled service platform, AgioNow, to support a full range of managed IT and cybersecurity services. Agio's new ...
$AGIO insiders have traded $AGIO stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales. We have seen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results